Lilly granted restraining order against Teva's generic Evista launch

16 March 2009

US drug major Eli Lilly has been granted a temporary restraining order preventing the launch of a generic version of Evista (raloxifene) by  Israel's Teva Pharmaceutical Industries. The latter had previously  stated that it was prepared to launch the copy-drug before pending  patent litigation being heard by the US District Court for the Southern  District of Indiana regarding the product had been completed. Lilly  maintains that Teva's challenge to its patent is without merit and says  it expects to prevail in the litigation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >






Company Spotlight